-
Citi Bullish On AbbVie As Allergan Deal Provides An Earnings Floor
Thursday, September 26, 2019 - 1:46pm | 331Read More...AbbVie Inc (NYSE: ABBV) shares are advancing to their highest level since early July following a positive analyst action on the stock. The Analyst Citigroup analyst Andrew Baum upgraded shares of AbbVie from Neutral to Buy with a $90 price target, suggesting roughly 25% upside from current...
-
Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever
Wednesday, October 18, 2017 - 9:07am | 365Read More...Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from $65 to $72. The new bullish stance stems from increased conviction of Merck's...
-
Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks
Wednesday, July 5, 2017 - 12:17pm | 394Read More...The Congressional Budget Office has said that the Senate version of the Republicans’ Affordable Care Act replacement bill could result in 22 million fewer Americans with health insurance. That dramatic reduction in coverage could have major implications for drug makers offering expensive...
-
Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
Tuesday, May 16, 2017 - 11:15am | 371Read More...Shares of Pfizer Inc. (NYSE: PFE) were trading lower by nearly 2 percent Tuesday morning after analysts at Citi downgraded the stock and offered three alternative recommendations. Citi's Andrew Baum downgraded Pfizer's stock rating from Neutral to Sell with a price target slashed from $38 to $31....
-
Citi Research Reevaluates Bristol-Myers, Lowers Price Target
Tuesday, September 20, 2016 - 9:13am | 367Read More...Expectations are for an “underwhelming subgroup analysis” when the CheckMate-026 trial is presented at the forthcoming ESMO conference, Citi’s Andrew Baum said in a report. He maintained a Buy rating on Bristol-Myers Squibb Co (NYSE: BMY), while reducing the price target from $...
-
Citi Doesn't See Merck's Lung Cancer Success Lasting Long
Monday, August 8, 2016 - 7:36am | 321Read More...Bristol-Myers Squibb Co (NYSE: BMY) unexpectedly announced the failure of the CheckMate-026 trial in non-small cell lung cancer [NSCLC]. While this development means that Merck & Co., Inc. (NYSE: MRK) would likely dominate the 1st line NSCLC market for patients with PDL1 high expressing...
-
Following Pfizer's Q2 Results, Citi Says Investors Remain Focused On Potential Breakup
Tuesday, August 2, 2016 - 2:26pm | 265Read More...Despite a second quarter earnings beat from Pfizer Inc. (NYSE: PFE), Citi said investors are focusing on the potential breakup of the company by the year-end. But, Citi still views the breakup as "unlikely." Citi, which has a Neutral rating and $37 price target on the stock,...
-
Citi Downgrades Novartis Following SAG Investigation
Tuesday, March 29, 2016 - 10:10am | 484Read More...Citi has downgraded Novartis AG (ADR) (NYSE: NVS) to Neutral from Buy on SAG investigation. Analyst Andrew Baum reported, "The ongoing action of the formidable State Attorney General (SAG) of the Southern District of NY, Preet Bharara, casts a reputational shadow over the incumbent Novartis...
-
Citi Says AbbVie Is Now A Buy
Tuesday, February 23, 2016 - 9:26am | 141Read More...Citi's Andrew Baum upgraded the rating for AbbVie Inc (NYSE: ABBV) from Neutral to Buy, while raising the price target from $56 to $65. He mentioned that the markets seem to be underestimating the probability that the company's Humira dosing patients will "prove resilient" in the ongoing IPR...
-
UPDATE: Citi Initiates Coverage On AbbVie, Sees Price Erosion Ahead
Monday, February 9, 2015 - 10:45am | 247Read More...Citi initiated coverage on AbbVie Inc (NYSE: ABBV) Monday with a Sell rating and $48 price target. Analyst Andrew Baum felt that the market has underestimated the “timing and magnitude” of Humira biosimilars. According to Baum, "the critical investment debate for AbbVie is...
-
Astrazeneca Down 3% Despite Citigroup Upgrade
Tuesday, April 22, 2014 - 1:16pm | 100Read More...On Tuesday, Citigroup upgraded shares of Astrazeneca (NYSE: AZN) from Neutral to Buy and raised the price target from $20.80 to $29.12. Analyst Andrew Baum believes the reported £60 billion bid from Pfizer (NYSE: PFE) “looks highly probable.” Although the Astrazeneca CEO, Ian Read, will likely try...
